High-dose ifosfamide and mitoxantrone (HDIM) in patients with relapsed or refractory Hodgkin’s lymphoma-Reference-Cited by-同舟云学术

High-dose ifosfamide and mitoxantrone (HDIM) in patients with relapsed or refractory Hodgkin’s lymphoma

Published:2016-04-22 Issue:7 Volume:95 Page:1129-1136
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Aurer Igor,Nemet Damir,Mitrović Zdravko,Dujmović Dino,Bašić-Kinda Sandra,Radman Ivo,Sertić Dubravka,Šantek Fedor,Kralik Marko,Dotlić Snježana,Mazić Sanja,Labar Boris

Funder

Croatian Ministry of Science and Education

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00277-016-2676-0.pdf

Reference22 articles.

1. Ansell SM (2014) Hodgkin lymphoma: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol 89:771–779

2. van den Neste E, Casasnovas O, Andre M, Touati M, Senecal D, Edeline V, Stamatoullas A, Fornecker L, Deau B, Gastinne T, Reman O, Gaillard I, Borel C, Brice P, Ferme C (2013) Classical Hodgkin’s lymphoma: the Lymphoma Study Association guidelines for relapsed and refractory adult patients eligible for transplant. Haematologica 98:1185–1195

3. Colwill R, Crump M, Couture F, Danish R, Stewart AK, Sutton DM, Scott JG, Sutcliffe SB, Brandwein JM, Keating A (1995) Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin’s disease before intensive therapy and autologous bone marrow transplantation. J Clin Oncol 13:396–402

4. Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, Boissevain F, Zschaber R, Muller P, Kirchner H, Lohri A, Decker S, Koch B, Hasenclever D, Goldstone AH, Diehl V, German Hodgkin’s Lymphoma Study Group, Lymphoma Working Party of the European Group for Blood and Marrow Transplantation (2002) Aggressive conventional chemotherapy compared with high dose chemotherapy with autologous haemopoietic stem cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomized trial. Lancet 359:2065–2071

5. Josting A, Rudolph C, Reiser M, Mapara M, Sieber M, Kirchner HH, Dorken B, Hossfeld DK, Diehl V, Engert A, Participating Centers (2002) Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin’s disease. Ann Oncol 13:1628–1635

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Vascular access for autologous peripheral blood stem cells collection by large volume leukapheresis: Single center experience;Journal of Clinical Apheresis;2023-11-08

2. Early and late adverse renal effects after potentially nephrotoxic treatment for childhood cancer;Cochrane Database of Systematic Reviews;2019-03-11

3. Challenges and perspectives in the immunotherapy of Hodgkin lymphoma;European Journal of Cancer;2017-11

4. Ifosfamide/mesna/mitoxantrone;Reactions Weekly;2016-08